Retrospective analysis of health claims to evaluate pharmacotherapies with potential for repurposing: Association of bupropion and stimulant use disorder remission

AMIA Annu Symp Proc. 2018 Dec 5:2018:1292-1299. eCollection 2018.

Abstract

Drug repurposing is the identification of novel indication(s) for existing medications. Health claims data provide a burgeoning resource to evaluate pharmacotherapies with repurposing potential. To demonstrate a workflow for drug repurposing using claims data, we assessed the association between prescription of bupropion and stimulant use disorder (StUD) remission. Using the Truven Marketscan database, 96,156 individuals with a StUD were identified. Logistic regression was used to model the association between new bupropion prescriptions and remission while controlling for age, sex, region, StUD severity, antidepressant co-prescriptions, and comorbid mood and attention disorders. Prescription of bupropion within 30 days offirst documented StUD diagnosis increased odds of a subsequent remission diagnosis by 2.1 times (99% confidence interval: 1.09-3.89) in individuals with an amphetamine use disorder, but not those with a cocaine use disorder. This work provides a framework for reverse-translational drug repurposing, which may be applied to many other medical conditions.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Bupropion / therapeutic use*
  • Central Nervous System Stimulants*
  • Cocaine-Related Disorders / drug therapy
  • Comorbidity
  • Drug Repositioning*
  • Female
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Odds Ratio
  • Remission Induction / methods
  • Retrospective Studies
  • Substance-Related Disorders / drug therapy*
  • Young Adult

Substances

  • Antidepressive Agents, Second-Generation
  • Central Nervous System Stimulants
  • Bupropion